Dyslipidemia is an important modifiable risk factor for CV disease and is primarily managed with statin therapy. Based on the positive CVOT data for certain nonstatin therapies, including the PCSK9 inhibitors and Vascepa, physicians are eagerly seeking the ability to reduce the mortality rate and the risk of CV morbidity in their dyslipidemia patients. We discuss how current therapies are differentiated based on the performance of key drug attributes and measure the impact of these attributes on physicians’ prescribing behavior. We also assess the most important unmet needs in the treatment of dyslipidemia and consider which emerging therapies, if any, can capitalize on these opportunities. Our conjoint analysis reveals the key trade-offs that surveyed physicians are willing to make for these attributes when considering new treatment options for dyslipidemia.
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 34 European cardiologists and endocrinologists fielded in January 2019
Key companies: Amarin Corporation, Amgen, and Sanofi/Regeneron Pharmaceuticals
Key drugs: Ezetimibe, statins, fibrates, Praluent, Repatha, Vascepa, and omega-3-acid ethyl ester (Lovaza)